First Commercial Medicare Advantage Plan Provides Payment for ReWalk 7 Personal Exoskeleton
Lifeward (NASDAQ:LFWD) has achieved a significant milestone by receiving its first payment from a commercial Medicare Advantage Plan for its ReWalk 7 Personal Exoskeleton. The company has reported accelerated claim processing times, with approvals now taking just 30-60 days, compared to previously longer timelines.
Following CMS's 2024 establishment of a Medicare reimbursement pathway for personal exoskeletons, Lifeward has successfully streamlined the claims process. The majority of Medicare claims are now being approved upon initial submission, eliminating the need for lengthy appeals processes.
Lifeward (NASDAQ:LFWD) ha raggiunto un importante traguardo ricevendo il primo pagamento da un piano commerciale Medicare Advantage per il suo ReWalk 7 Personal Exoskeleton. L'azienda segnala tempi di elaborazione delle richieste accelerati, con approvazioni che richiedono ora solo 30-60 giorni, rispetto a tempistiche precedentemente più lunghe.
In seguito all'istituzione nel 2024 da parte del CMS di un percorso di rimborso Medicare per gli esoscheletri personali, Lifeward ha snellito con successo il processo di gestione delle richieste. La maggior parte delle pratiche Medicare viene ora approvata già alla prima presentazione, eliminando la necessità di lunghi ricorsi.
Lifeward (NASDAQ:LFWD) ha alcanzado un hito importante al recibir su primer pago de un plan comercial Medicare Advantage por su ReWalk 7 Personal Exoskeleton. La compañía informa de tiempos de tramitación acelerados, con aprobaciones que ahora tardan solo 30-60 días, frente a plazos anteriormente más largos.
Tras el establecimiento en 2024 por parte de CMS de una vía de reembolso de Medicare para exoesqueletos personales, Lifeward ha optimizado con éxito el proceso de reclamaciones. La mayoría de las solicitudes a Medicare se están aprobando en la presentación inicial, evitando la necesidad de largos procesos de apelación.
Lifeward (NASDAQ:LFWD)가 ReWalk 7 Personal Exoskeleton에 대해 상업용 Medicare Advantage 플랜으로부터 첫 번째 지급을 받으며 중요한 이정표를 달성했습니다. 회사는 청구 처리 속도가 빨라져 승인까지 걸리는 시간이 이전보다 짧아져 이제 단 30–60일만 소요된다고 보고했습니다.
CMS가 2024년에 개인용 외골격에 대한 Medicare 환급 경로를 마련한 이후 Lifeward는 청구 절차를 성공적으로 간소화했습니다. 대부분의 Medicare 청구가 최초 제출 시 승인되어 긴 항소 절차가 불필요해졌습니다.
Lifeward (NASDAQ:LFWD) a franchi une étape importante en recevant son premier paiement d'un plan commercial Medicare Advantage pour son ReWalk 7 Personal Exoskeleton. L'entreprise fait état d'un accélération des délais de traitement des demandes, les approbations ne prenant désormais que 30-60 jours, contre des délais auparavant plus longs.
Suite à l'établissement en 2024 par le CMS d'une voie de remboursement Medicare pour les exosquelettes personnels, Lifeward a réussi à rationaliser le processus de réclamation. La majorité des demandes Medicare sont désormais approuvées dès la première soumission, éliminant le besoin de longs appels.
Lifeward (NASDAQ:LFWD) hat einen wichtigen Meilenstein erreicht und die erste Zahlung von einem kommerziellen Medicare Advantage Plan für sein ReWalk 7 Personal Exoskeleton erhalten. Das Unternehmen berichtet von beschleunigten Bearbeitungszeiten für Ansprüche, mit jetzt nur noch 30–60 Tagen bis zur Genehmigung, verglichen mit zuvor längeren Fristen.
Nachdem CMS 2024 einen Medicare-Erstattungsweg für persönliche Exoskelette eingerichtet hat, hat Lifeward den Abwicklungsprozess erfolgreich vereinfacht. Die Mehrheit der Medicare-Anträge wird inzwischen bei der ersten Einreichung genehmigt, sodass langwierige Widerspruchsverfahren entfallen.
- None.
- None.
Medicare Advantage claim processed in less than thirty days
Additional progress with traditional Medicare claim approvals has accelerated timelines to payment in 2025
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, announced today that it received its first payment from a commercial Medicare Advantage Plan for a ReWalk 7 Personal Exoskeleton.
“As we continue to submit claims to broaden access to exoskeletons for individuals living with spinal cord injury, we are seeing momentum, both in the number of payers participating and also in how quickly claims for the ReWalk 7 Personal Exoskeleton are being approved” said Mark Grant, CEO of Lifeward. “We’re especially pleased to begin including Medicare Advantage Plans among our reimbursing payers, helping ensure consistent access and equality of care across the full range of Medicare options.”
In 2024, the Centers for Medicare & Medicaid Services (“CMS”) finalized a Medicare reimbursement pathway for personal exoskeleton use. Since then, Lifeward has worked to refine and accelerate claims processing. As of 2025, the majority of Medicare claim approvals are occurring at the initial submission level, bypassing a lengthy denials and appeals process and allowing recent Medicare claims to be processed and paid in as little as 30-60 days.
About Lifeward
Lifeward designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community. Our mission at Lifeward is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities. We are committed to delivering groundbreaking solutions that empower individuals to do what they love. The Lifeward portfolio features innovative products including the ReWalk Exoskeleton, the AlterG Anti-Gravity System, the ReStore Exo-Suit, and the MyoCycle FES System. Founded in 2001, Lifeward has operations in the United States, Israel, and Germany.
Lifeward®, ReWalk®, ReStore®, and Alter G® are registered trademarks of Lifeward Ltd. and/or its affiliates.
Forward-Looking Statements
In addition to historical information, this press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward looking statements may include projections regarding the Company's future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Important factors that could cause the Company’s actual results to differ materially from those indicated in the forward looking statements include, among others: the acceptance of the ReWalk 7 Personal Exoskeleton by healthcare professionals and patients; uncertainties associated with future clinical trials and the clinical development process, the product development process and FDA regulatory submission review and approval process; the Company's ability to have sufficient funds to meet certain future capital requirements, which could impair the Company's efforts to develop and commercialize existing and new products; the Company's ability to maintain and grow its reputation and the market acceptance of its products; the Company's ability to achieve reimbursement from third-party payors, including CMS, for its products; the Company's limited operating history and its ability to leverage its sales, marketing and training infrastructure; the Company's expectations as to its clinical research program and clinical results; the Company's expectations regarding future growth, including its ability to increase sales in its existing geographic markets and expand to new markets; the Company's ability to obtain certain components of its products from third-party suppliers and its continued access to its product manufacturers; the Company’s ability to navigate any difficulties associated with moving production of its AlterG Anti-Gravity Systems to a contract manufacturer and transitioning the manufacturing of its ReWalk products to its in-house manufacturer; the Company's ability to improve its products and develop new products; the Company's compliance with medical device reporting regulations to report adverse events involving the Company's products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on the Company's ability to market and sell its products; the Company's ability to gain and maintain regulatory approvals; the Company's ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; the risk of a cybersecurity attack or breach of the Company's IT systems significantly disrupting its business operations; the Company's ability to use effectively the proceeds of its offerings of securities; and other factors discussed under the heading "Risk Factors" in the Company’s annual report on Form 10-K, as amended, for the year ended December 31, 2024 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause the Company’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
Lifeward Media Relations:
Kathleen O’Donnell
Vice President, Marketing & New Business Development
Lifeward
E: media@golifeward.com
Lifeward Investor Contact:
Almog Adar
Chief Financial Officer
Lifeward
E: ir@golifeward.com
FAQ
What milestone did Lifeward (LFWD) achieve with Medicare Advantage Plans in 2025?
How long does it take for ReWalk 7 exoskeleton Medicare claims to be processed in 2025?
When did CMS establish the Medicare reimbursement pathway for personal exoskeletons?
What improvements has Lifeward made to their Medicare claims process?
How will Medicare Advantage Plan coverage benefit Lifeward's ReWalk 7 users?
